Suppression of the cuproptosis mechanism by the oncogene RASGRP2 in driving osteosarcoma progression.
5 affiliations
- 1Department of Orthopedic Trauma, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), Zhuhai, China.
- 2The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- 3Department of Emergency, Hengqin Hospital, The First Affiliated Hospital of Guangzhou Medical University, Zhuhai, China.
- 4Department of Joint and Sports Medicine, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), Zhuhai, China.
- 5Department of Sports Medicine, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Speed Capability, The Guangzhou Key Laboratory of Precision Orthopedics and Regenerative Medicine, School of Medicine, Jinan University, Guangzhou, China.
Abstract
Osteosarcoma remains a life-threatening malignancy with poor outcomes in patients, who may experience metastatic disease even with multiagent chemotherapy. Cuproptosis, a recently discovered copper-dependent cell death mechanism, represents a potential therapeutically relevant vulnerability in cancer. However, the mechanisms underlying cuproptosis resistance in osteosarcoma have not been clarified, and whether oncogenic pathways enable tumor cells to evade cuproptotic death remain unknown. This study aims to investigate the functional role of the oncogene RASGRP2 in osteosarcoma progression and to determine whether RASGRP2 suppresses the cuproptosis mechanism and thereby confers resistance to copper-induced cell death. We investigated RASGRP2 expression in osteosarcoma tumors and cell lines using public datasets and laboratory assays. In functional studies, small interfering RNA (siRNA) knockdown and lentiviral overexpression were used to assess cell proliferation, colony formation, and tumor growth in xenograft models. In mechanistic studies, cuproptosis-related gene expression, intracellular copper accumulation, and sensitivity to elesclomol-copper treatment were examined through real-time quantitative polymerase chain reaction, Western blotting, copper assays, and viability assays. RASGRP2 was significantly upregulated in osteosarcoma tissues and cell lines, with high expression correlating with poor overall survival and disease-free survival. RASGRP2 knockdown suppressed cell proliferation and colony formation in vitro, while overexpression promoted tumor growth in vivo. Bioinformatic analysis revealed inverse correlations between RASGRP2 and key cuproptosis mediators (FDX1, DLAT, ATP7B, LIAS, and DLD). RASGRP2 depletion upregulated these cuproptosis genes at the messenger RNA and protein levels, increased intracellular copper accumulation, and sensitized osteosarcoma cells to elesclomol-copper-induced cell death both in vitro and in colony formation assays. RASGRP2 functions as a critical oncogenic driver in osteosarcoma that confers resistance to cuproptosis by suppressing key cuproptosis machinery. These findings establish the RASGRP2-cuproptosis axis as a novel therapeutic target and suggest that combining RASGRP2 inhibition with copper ionophore therapy may represent a promising strategy for treating this aggressive malignancy.
Related
- FDX1 suppresses acute myeloid leukemia progression and reverses cuproptosis resistance via the ROS/p53/ME1 axis
- URGCP promotes osteosarcoma progression by regulating the ESCRT-III subunit CHMP4B
- LncRNA AP003469.2 promotes hepatocellular carcinoma progression by regulating cuproptosis via the miR-4732-3p/LIPT1 axis
- An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy
- The Osteosarcoma Tumor Microenvironment: Supportive of Tumor Progression, Hostile to Immunity, but Therapeutically Targetable.
BibTeX
@article{chen2026suppression,
title = {{Suppression of the cuproptosis mechanism by the oncogene RASGRP2 in driving osteosarcoma progression.}},
author = {Jinquan Chen and Dandong Luo and Jie Cui and Zhiyong Shu and Cheng Wang and Yuwen Jiang and Huajun Wang and Xiaofei Zheng},
journal = {Translational cancer research},
year = {2026},
month = oct,
doi = {10.21037/tcr-2026-1-0064},
url = {https://europepmc.org/article/MED/42997764},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Suppression of the cuproptosis mechanism by the oncogene RASGRP2 in driving osteosarcoma progression.
AU - Jinquan Chen
AU - Dandong Luo
AU - Jie Cui
AU - Zhiyong Shu
AU - Cheng Wang
AU - Yuwen Jiang
AU - Huajun Wang
AU - Xiaofei Zheng
PY - 2026
DA - 2026/10/23
JO - Translational cancer research
DO - 10.21037/tcr-2026-1-0064
UR - https://europepmc.org/article/MED/42997764
AB - Osteosarcoma remains a life-threatening malignancy with poor outcomes in patients, who may experience metastatic disease even with multiagent chemotherapy. Cuproptosis, a recently discovered copper-dependent cell death mechanism, represents a potential therapeutically relevant vulnerability in cancer. However, the mechanisms underlying cuproptosis resistance in osteosarcoma have not been clarified, and whether oncogenic pathways enable tumor cells to evade cuproptotic death remain unknown. This study aims to investigate the functional role of the oncogene RASGRP2 in osteosarcoma progression and to determine whether RASGRP2 suppresses the cuproptosis mechanism and thereby confers resistance to copper-induced cell death. We investigated RASGRP2 expression in osteosarcoma tumors and cell lines using public datasets and laboratory assays. In functional studies, small interfering RNA (siRNA) knockdown and lentiviral overexpression were used to assess cell proliferation, colony formation, and tumor growth in xenograft models. In mechanistic studies, cuproptosis-related gene expression, intracellular copper accumulation, and sensitivity to elesclomol-copper treatment were examined through real-time quantitative polymerase chain reaction, Western blotting, copper assays, and viability assays. RASGRP2 was significantly upregulated in osteosarcoma tissues and cell lines, with high expression correlating with poor overall survival and disease-free survival. RASGRP2 knockdown suppressed cell proliferation and colony formation in vitro, while overexpression promoted tumor growth in vivo. Bioinformatic analysis revealed inverse correlations between RASGRP2 and key cuproptosis mediators (FDX1, DLAT, ATP7B, LIAS, and DLD). RASGRP2 depletion upregulated these cuproptosis genes at the messenger RNA and protein levels, increased intracellular copper accumulation, and sensitized osteosarcoma cells to elesclomol-copper-induced cell death both in vitro and in colony formation assays. RASGRP2 functions as a critical oncogenic driver in osteosarcoma that confers resistance to cuproptosis by suppressing key cuproptosis machinery. These findings establish the RASGRP2-cuproptosis axis as a novel therapeutic target and suggest that combining RASGRP2 inhibition with copper ionophore therapy may represent a promising strategy for treating this aggressive malignancy.
SN - 2218-676X
SN - 2219-6803
ER -